An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy

Completed · Not applicable

Conditions studied: Mycobacterium Avium-Intracellulare Infection, HIV Infections

In brief

To evaluate the efficacy and safety of azithromycin given chronically for the treatment of Mycobacterium avium (MAC) bacteremia in patients failing or intolerant of current available MAC therapy.

Key facts

Study ID

NCT00002089

Run by

Pfizer

Last updated by the study team

2005-06-24

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Disseminated MAC as defined by current (within the last month) positive blood, bone marrow, or liver biopsy culture for MAC, and considered symptomatic (fever, night sweats, anorexia, weight loss, fatigue, or malaise).
• At least 2 months of prior treatment with available combination MAC therapy or less than 2 months of such accompanied by unacceptable adverse effects.
• Life expectancy of more than 2 weeks.
• Approval of eligibility from Pfizer Clinical Monitor.
• Consent of parent or guardian if under legal age of consent.
• NOTE:
• Patients who have completed acute treatment with azithromycin for MAC in protocol 066-131 or 066-148 will be exempt from inclusion criteria 1 and 2 and can continue therapy through this protocol if their physician feels they have benefitted from prior azithromycin therapy.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms and conditions are excluded:
• Known hypersensitivity or intolerance to macrolide antibiotics.
• Inability to take oral medications or current condition that is likely to interfere with absorption (e.g., gastrectomy).
• Concurrent Medication:
• Excluded:
• Other MAC therapy instituted during the first 2 months of the study.
• Other investigational drugs, with the exception of those available through a Treatment IND program.
• Patients with the following prior conditions are excluded:
• History of hypersensitivity or intolerance to azithromycin.
• Prior Medication:
• Excluded:
• Other investigational drugs within 7 days of enrollment, with the exception of Treatment IND drugs (such as ddC).

Where it is running

• Pfizer Central Research — Groton, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.